



A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment

Anje Cauwels, Sandra van Lint, Geneviève Garcin, Jennyfer Bultinck, Franciane Paul, Sarah Gerlo, José van Der Heyden, Yann Bordat, Dominiek Catteeuw, Lode de Cauwer, et al.

► To cite this version:

Anje Cauwels, Sandra van Lint, Geneviève Garcin, Jennyfer Bultinck, Franciane Paul, et al.. A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment. *OncoImmunology*, 2017, 7 (3), pp.e1398876. 10.1080/2162402X.2017.1398876 . hal-02322002

HAL Id: hal-02322002

<https://hal.science/hal-02322002>

Submitted on 24 Oct 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**A safe and highly efficient tumor-targeted type I interferon immunotherapy
depends on the tumor microenvironment**

Anje Cauwels¹, Sandra Van Lint¹, Geneviève Garcin², Jennyfer Bultinck^{1,3}, Franciane Paul², Sarah Gerlo¹,
José Van der Heyden¹, Yann Bordat², Dominiek Catteeuw¹, Lode De Cauwer^{1,4}, Elke Rogge¹, Annick
Verhee¹, Gilles Uzé^{2*} & Jan Tavernier^{1*#}

* shared senior authors

corresponding author

1 Cytokine Receptor Laboratory, Flanders Institute of Biotechnology, VIB Medical Biotechnology
Center, Faculty of Medicine and Health Sciences, Ghent University, A. Baertsoenkaai 3, 9000
Ghent, Belgium

2 CNRS UMR 5235, University Montpellier, Place Eugène Bataillon, 34095 Montpellier, France

3 Present address: Oxyrane, Technologiepark 3, 9052 Zwijnaarde-Gent, Belgium

4 Present address: Argenx BVBA, Industriepark Zwijnaarde 7, 9052 Zwijnaarde-Gent, Belgium

Running title: AcTaferons as cancer immunotherapy

Key words: Immunotherapy, type I interferon, tumor microenvironment, AcTaferon, dendritic cells,
toxicity, targeting, engineered immunocytokine, checkpoint inhibitors

21

22 **Abstract**

23

24 Despite approval for the treatment of various malignancies, clinical application of cytokines such as type
25 I interferon (IFN) is severely impeded by their systemic toxicity. AcTakines (Activity-on-Target cytokines)
26 are optimized immunocytokines that, when injected in mice, only reveal their activity upon cell-specific
27 impact. We here show that type I IFN-derived AcTaferon targeted to the tumor displays strong antitumor
28 activity without any associated toxicity, in contrast with wild type IFN. Treatment with CD20-targeted
29 AcTaferon of CD20⁺ lymphoma tumors or melanoma tumors engineered to be CD20⁺, drastically reduced
30 tumor growth. This antitumor effect was completely lost in IFNAR- or Batf3-deficient mice, and depended
31 on IFN signaling in conventional dendritic cells. Also the presence of, but not the IFN signaling in, CD8⁺ T
32 lymphocytes was critical for proficient antitumor effects. When combined with immunogenic
33 chemotherapy, low-dose TNF, or immune checkpoint blockade strategies such as anti-PDL1, anti-CTLA4
34 or anti-LAG3, complete tumor regressions and subsequent immunity (memory) were observed, still
35 without any concomitant morbidity, again in sharp contrast with wild type IFN. Interestingly, the
36 combination therapy of tumor-targeted AcTaferon with checkpoint inhibiting antibodies indicated its
37 ability to convert nonresponding tumors into responders. Collectively, our findings demonstrate that
38 AcTaferon targeted to tumor-specific surface markers may provide a safe and generic addition to cancer
39 (immuno)therapies.

40

41

Introduction

Interferon-alpha (IFN α) is a type I IFN (IFN), approved for the treatment of some neoplasms, including hematological (hairy cell leukemia and other lympho- and myeloproliferative neoplasms) and solid cancers (melanoma, renal cell carcinoma, Kaposi's sarcoma).¹ Unfortunately, IFN therapy experienced variable and unpredictable success in the clinic, and is severely limited due to side effects such as flu-like symptoms, leukopenia, anemia, hepatotoxicity, cognitive dysfunction, neurologic toxicity and depression².

It was initially assumed that the direct inhibitory effect of IFN on tumor cells was essential. Indeed, IFNs regulate the expression of genes affecting tumor cell growth, proliferation, differentiation, survival, migration and other functions,³ but it is known since a long time that the key mechanism of IFN antitumor activity is more likely indirect, via immune activation.⁴ Several host immune cells, including dendritic cells (DC), T and B lymphocytes, Natural Killer (NK) cells and macrophages, respond to IFN and may be involved in antitumor activity.^{3, 5} Furthermore, endogenous IFN is essential for many anti-cancer therapies, including chemotherapy, radiotherapy, immunotherapies and checkpoint inhibition.⁵

Safe exploitation of the clinical potential of IFN, and many other cytokines, requires strategies to target their activity to selected target cells only, thus avoiding systemic toxicity. One strategy to accomplish this is by developing immunocytokines, fusions of wild type (WT) cytokines coupled to antibodies recognizing cell-specific surface-expressed markers. For most immunocytokines in development, an approximately 10-fold increase in targeted activity is achieved, increasing the therapeutic index modestly.^{6, 7} Indeed, even if coupled to a targeting moiety, WT cytokines still exert unwanted effects on untargeted cells while in passage to their target, due to the ubiquitous expression of their cognate receptors. Related to the latter, WT (immuno)cytokines may also disappear from the circulation before reaching their target cells (the so-called "sink effect").⁸ To improve the therapeutic index of toxic cytokines, we developed AcTakines

(Activity-on-Target Cytokines), optimized immunocytokines, using mutated cytokines with strongly reduced affinity for their receptor complex instead of WT cytokines. Fusing the mutated cytokine to cell-specific targeting domains selectively restores AcTakine activity on the selected cell population only. Consequently, AcTakines are much less potent to signal while traveling through the body. We have proven the basic AcTakine concept of IFN using human IFN α 2 (which is not active on mouse cells) with a Q124R mutation rendering it about 100-fold less active on mouse cells than murine (m) IFN α .⁹ We coined this mutated and targeted¹⁰ IFN 'AcTaferon' (AFN), and evaluated its potential as a safe and generic cancer treatment in preclinical mouse models by targeting its activity to the tumor.

Results

Tumor-targeted delivery of IFN activity: mCD20–AcTaferon proof-of-principle

To study the antitumor potential of targeting type I IFN activity specifically to tumor cells, we coupled hIFN α 2-Q124R⁹ (from now on designated as ‘AcTaferon’ or AFN) to a VHH single domain antibody (sdAb) targeting mCD20 (**Fig. 1A**). As control (untargeted) constructs, we used AFN coupled to sdAb targeting either hCD20, GFP or Bcl110, epitopes absent in the mouse (confirmed by imaging).¹¹ CD20 is a B lymphocyte-specific antigen present on all B cell stages except early pro-B lymphocytes and plasma cells. We preferred mCD20 targeting in view of the success of CD20 antibodies (rituximab, obinutuzumab) in patients with B cell malignancies, which clearly proves the efficacy of CD20 as a tumor-associated antigen (TAA) useful for therapy. Since the frequently used CD20⁺ mouse B cell lymphoma A20 is highly sensitive to IFN, we chose this model to obtain initial *in vivo* antitumor proof-of-concept.

CD20-targeting of IFN activity was demonstrated in both primary CD19⁺ B cells, activated either *in vitro* (not shown) or *in vivo* (**Fig. 1B**), as well as using CD20⁺ IFN-sensitive A20 cells (**Fig. 1C**). For primary B cells, IFN signaling was evaluated via intracellular phospho-STAT1 determination (**Fig. 1B**). Importantly, mCD20-targeting of wild type (WT) hIFN (which is not active on mouse cells) did not induce any phospho-STAT1 signal in murine B cells (**Supplementary Fig. 1**). For A20, the anti-proliferative efficacy *in vitro* was determined, indicating a 1,000-fold increased activity of AFN due to targeting (**Fig. 1C**). Because of this remarkable targeting efficacy, we decided to use A20 to evaluate whether mCD20-targeted AFN can be efficiently delivered to CD20⁺ tumors *in vivo*. In A20-bearing mice, treatment with mCD20-AFN prevented tumor growth (**Fig. 1D**) comparable to WT mIFN targeted to the tumors or not (the latter using sdAb recognizing hCD20 instead of mCD20). Untargeted hCD20-AFN or WT hIFN-coupled mCD20 sdAb (which does not have detectable IFN signaling capacity in mice) did not have a significant antitumor effect.

Targeted delivery of AcTaferon activity to the tumor host-dependently controls tumor growth without systemic toxicity

In some cancers, such as B cell malignancies, IFN exerts direct antitumor effects. Although combination therapies with anti-CD20 and IFN showed improved efficiency in B cell lymphomas, including in targeting strategies,¹² we envisaged the development of a non-toxic safe antitumor therapy applicable to various tumor types, including non-B cell and IFN-insensitive malignancies. Central to this concept is the observation that the antitumor efficacy of IFN may also depend on indirect effects via activation of immune cells.⁴ Recombinant IFN α 2 was in 1995 the first cytokine to be approved for the treatment of cancer, i.e. malignant melanoma. Until the approval of checkpoint inhibitors, IFN was actually the only effective adjuvant therapy for melanoma patients at high risk for recurrence and death.² Since 2011, several immunotherapies have been approved, primarily for the treatment of advanced metastatic melanoma. In view of this, we decided to evaluate the use of tumor-targeted AFNs by using the B16 melanoma model, which is not sensitive to the anti-proliferative activity of IFN, and is considered a non- or low-immunogenic tumor, reflecting the poor immunogenicity of metastatic tumors in humans, thus representing a “tougher test” for immunotherapy.^{13, 14} To enable the use of our proof-of-principle mCD20-AFN, we engineered B16-mCD20⁺ and B16-hCD20⁺ clones using CD20 as a surrogate tumor-specific surface marker.

In mice bearing a B16-mCD20 tumor, mCD20-AFN treatment inhibited tumor growth comparable to WT mIFN, while untargeted hCD20-AFN only exhibited some minor, mostly non-significant, antitumor effect starting after 3-4 treatments (**Fig. 2A**). Targeting WT hIFN (mCD20-hIFN) to the mCD20⁺ tumors did not have any effect, excluding antitumor activities induced by the anti-mCD20 sdAb on its own. Although mCD20-AFN and mIFN had comparable antitumor effects when used at the same protein concentration (**Fig. 2A-B**), there was a dramatic difference in systemic toxicity. While mIFN caused body weight loss, severe thrombocytopenia, anemia and leukopenia, AFN therapy did not (**Fig. 2C-I**). Reduced platelet

numbers combined with increased platelet sizes, as seen after mIFN (**Fig. 2D-E**), indicate platelet destruction.

Bioactivity measurements of mIFN and mCD20-AFN, on murine cells which do not express mCD20, revealed that the AFN dose used for therapy was at least 1,000-fold lower than mIFN. For the representative experiment (**Fig. 2**), the doses injected were 6,000,000 and 5,500 IU for mIFN and mCD20-AFN, respectively. Injection of lower doses of WT mIFN reduced systemic toxicity concomitantly with the antitumor potential (**Fig. 3**). In contrast with lower doses (5,500 or 1,100 IU) of mCD20-AFN, lower doses of mIFN did not inhibit tumor growth, not even when targeted to the tumor as immunocytokine (**Fig. 3A**).

As already mentioned, AFN therapy did not cause hematological deficits. However, although not significant, lymphocyte counts were consistently lower after mCD20-AFN (**Fig. 2I**). Flow cytometry revealed partial B cell depletion from circulation, and normal CD8⁺ and CD4⁺ populations, in line with specific AFN targeting to CD20⁺ cells (**Supplementary Fig. 2**). Lowering the mCD20-AFN dose to 1,100 IU resulted in efficient tumor inhibition (**Fig. 3A**) without the partial lymphocyte depletion (**Fig. 3B**), indicating that B-lymphopenia is not required for antitumor responses. To unequivocally evaluate whether B cells are involved, we employed B16-hCD20⁺ tumors. Treatment with hCD20-AFN was equally potent as hCD20-mIFN, without lymphopenia (**Supplementary Fig. 3**).

The B16 melanoma model was chosen partly because there is no anti-proliferative effect of mCD20-AFN on B16-mCD20 cells *in vitro* (not shown). To confirm that the *in vivo* antitumor effects depend on host cells, we used mice lacking functional IFNAR1 (IFNAR1^{-/-}). As shown in **Fig. 4A**, mCD20-targeted mIFN or AFN were indeed ineffective in IFNAR1^{-/-}, in contrast to WT mice. Although these experiments indicate the crucial involvement of IFN signaling in host cells, direct effects of IFN on tumor cells that may contribute to antitumor efficacy (e.g. by releasing chemokines attracting the immune cells necessary for tumor cell eradication¹⁵) could also be involved. To evaluate this, we genetically engineered B16-mCD20⁺ tumor cells

that lack IFNAR1. As shown in **Fig. 4B**, the absence of IFNAR1 on the tumor cells did not significantly affect the antitumor effectiveness of mCD20-AFN, indicating that IFN signaling in the tumor cells is not crucial. However, mCD20-targeted AFN did not prevent tumor growth of B16-hCD20⁺ tumor cells, in contrast to hCD20-targeted AFN (**Fig. 4C**), demonstrating that targeting to the tumor cells (and thus the tumor microenvironment) is critical. Moreover, since our hCD20 sdAb is not cross-reactive with mCD20 (not shown), the antitumor effectiveness of hCD20-AFN in the B16-hCD20 model is not accompanied by partial lymphocyte depletion in mice (**Fig. 4D**). These results imply that the lymphopenia that can be observed is entirely due to anti-CD20 effects, and that the lymphopenia and IFN effects on B cells are not critically involved in the antitumor response.

Tumor-targeted AcTaferon effects critically depend on DC and CTL

In the cancer-immunity cycle described by Chen and Mellman,¹⁶ priming and activation of tumor-killing cytotoxic T lymphocytes (CTLs) represents a crucial step, for which activation and maturation of antigen-presenting DCs is key. A specific DC subset is essential for CTL responses in mice and men. This XCR1⁺ Clec9A⁺ conventional (c) DC1 subset, also known as CD8⁺ DC in mice and CD141⁺ or BDCA3⁺ DC in humans, displays superior cross-presentation capacities and requires type I IFN signaling for efficient tumor rejection.¹⁷⁻²³ As cDC1 require the Batf3 transcription factor for their differentiation, deletion of *Batf3* ablates their development.²⁴ Experiments in cDC1-deficient *Batf3*^{-/-} mice indicated the absolute requirement for cDC1 for the antitumor efficacy of tumor-targeted AFN (**Fig. 4E**). Also in mice where type I IFN signaling is absent in cDC only (*CD11c-IFNAR*^{-/-}),¹⁹ mCD20-AFN could not prevent tumor growth (**Fig. 4F**). The most important cells to destroy cancer cells and control tumor growth are believed to be the CD8⁺ CTL. They get selectively activated to recognize tumor cells by cDC1 cross-presenting tumor antigen. Indeed, depletion of CD8⁺ cells largely reduced mCD20-AFN antitumor efficacy (**Fig. 4G**). Still, a minor but

significant antitumor effect was seen in CD8-depleted conditions, suggesting the involvement of other immune cells as well. CD4 depletion, however, did not affect antitumor efficacy of mCD20-AFN (not shown). In contrast to CD11c-IFNAR^{-/-} (**Fig. 4F**), mCD20-AFN could still prevent tumor growth in mice lacking IFN signaling in T cells (CD4-IFNAR^{-/-}), demonstrating the requirement for IFN signaling in DC rather than T lymphocytes (**Fig. 4H**).¹⁹

DC activation and T cell proliferation induced by targeted AcTaferon delivery

To evaluate DC activation, we analyzed different populations isolated from tumor-draining lymph nodes after treatment with mCD20-targeted or untargeted AFN. While untargeted (Bcl10-coupled) AFN had a moderate effect on the expression of PDL1, MHCII, CD80, CD86 and CD40 in XCR1⁺ cDC1, mCD20-AFN treatment was clearly much better (**Fig. 5A upper row**). Of note, mCD20-AFN also significantly increased the activation of CD11b⁺ cDC2 in comparison with untargeted AFN (**Fig. 5A lower row**). Similar effects were also seen in non-tumor-draining lymph nodes (not shown).

CD8⁺ CTLs are considered the most important cells to control tumor growth by killing cancer cells. Treatment with mCD20-tumor-targeted AFN was much more efficient than PBS or untargeted AFN to induce tumor-specific activated CD8⁺ effector T cells (expressing high levels of CD44 and low levels of CD62L) in lymph nodes and in the tumors themselves (**Fig. 5B, E**). In addition, mCD20-AFN also significantly increased tumor-antigen-specific CTL proliferation in the lymph nodes (**Fig. 5C**).

Complete and safe tumor eradication by tumor-targeted AcTaferon in combination treatments

The cancer-immunity cycle indicates the sequential involvement of several steps necessary for tumor eradication, requiring various immune cells and signals, and possibilities to interact or influence¹⁶. First of

all, we examined whether chemotherapy causing immunogenic cell death could enhance tumor-targeted AFN therapy. Doxorubicin is such an anthracycline routinely used in the clinic. Used in a non-curative dose, doxorubicin synergized with mIFN or mCD20-AFN to completely eradicate B16-mCD20 tumors (**Fig. 6A**). Combined with mIFN, doxorubicin dramatically amplified toxicity resulting in exaggerated weight loss, hematological deficiency and even 100% mortality (**Fig. 6B-D**). In stark contrast, mCD20-AFN plus doxorubicin completely destroyed tumors without any detectable toxicity or mortality (**Fig. 6A-D**).

To facilitate tumor penetration of activated CTL and other immune cells involved in tumor eradication, we next combined IFN or mCD20-AFN with Tumor Necrosis Factor (TNF), known to activate and permeabilize endothelium in preclinical models and isolated limb perfusion in patients.^{25, 26} Low-dose TNF did not have an antitumor effect as such, but strongly synergized with mIFN or mCD20-AFN to fully destroy the B16-mCD20 tumor (**Fig. 6E**). Comparable to doxorubicine, low-dose TNF also fatally worsened the toxicity of mIFN, but not of mCD20-AFN (**Fig. 6F-H**).

Recently, immune checkpoint blockade strategies have become very efficient therapeutic options for many different malignancies. Both anti-CTLA4 and anti-PD1 treatments were first approved for advanced metastatic melanoma and show long-term cure in up to 40% of patients.²⁷ Unfortunately, most patients suffer from severe adverse effects, especially when treatments are combined.²⁸ In addition, the majority of patients are still either resistant to immunotherapy, or they relapse.¹⁸ Recently, endogenous IFN was shown to be involved not only in conventional anti-cancer therapies such as chemo- and radiotherapy,^{5, 29, 30} but also in immune checkpoint blockade efficacy.^{18, 31, 32} Considering this, we combined mCD20-AFN with a neutralizing anti-PDL1 sdAb. The rationale for this was further boosted by PDL1 analysis; mIFN and mCD20-AFN increased PDL1 expression on B16 cells *in vitro* and *in vivo* (**Supplementary Fig. 4**). Anti-PDL1 sdAb therapy significantly prolonged tumor stasis caused by mCD20-AFN and increased the number of tumor-free mice (**Fig. 6I**). To escape CTL-mediated tumor killing following anti-PD1 therapy, upregulation of CTLA4 expression on tumor-infiltrating or –resident lymphocytes, and *vice versa*, has been described.³³

³⁴ Therefore, we decided to add anti-CTLA4 and anti-OX40 antibodies to deplete intratumoral regulatory T cells³⁵ to our anti-PDL1 treatment regime. This resulted in AFN-induced tumor shrinkage in all mice (**Fig. 6J**). In control mice, anti-PDL1 as such had no effect (**Fig. 6I**), while anti-CTLA4 + anti-OX40 slowed down tumor growth (**Fig. 6J**). Although targeting the PDL1 and CTLA4 checkpoints has shown promising efficacy in several cancer types, several problems and questions still need to be resolved, such as the cause of resistance in many patients, their inefficacy in certain tumor types, as well as the development of severe adverse side effects. Lymphocyte-activation gene-3 (LAG3) is another vital checkpoint implicated in immunotherapy escape.³⁶ As shown in **Fig. 6K**, tumor-targeted AFN was capable of converting the nonresponsive B16 tumors into anti-LAG3 therapy responders, resulting in 40% tumor-free mice. Importantly, adding anti-PDL1, anti-CTLA4, anti-OX40, or anti-LAG3 to AFN therapy did not cause extra toxicity (**Supplementary Fig. 5-6**).

AcTaferon treatment provides tumor immunity

As certain combinations completely eradicated tumors (**Fig. 6**), we evaluated whether therapy induced immunity. Usually, AFN treatment was given until 16-17 days after initial tumor inoculation. If the successfully treated mice were still tumor-free on day 35, they were re-challenged with tumor cells on the contralateral flank. While all control (naive) mice developed a tumor within 7 days (**Fig. 7A**), 70% of AFN-treated tumor-free mice did not develop a new tumor in the next 2 months (**Fig. 7B**). Mice that developed a tumor did so later than naive mice. In addition, mice treated on days 5-10 following inoculation of their first tumor were challenged contralaterally on day 12. While all naive or PBS-treated mice developed a second tumor during the next 2 weeks (**Fig. 7C**), 65% of the AFN-treated animals did not (**Fig. 7D**).

Discussion

Type I IFN has long been approved for the treatment of several malignancies. The leading indications for its use in oncology include melanoma, renal cell carcinoma, AIDS-related Kaposi's sarcoma, follicular lymphoma, hairy cell leukemia, and chronic myelogenous leukemia.¹ In addition, endogenous IFN is critical for cancer immunosurveillance³⁷ as well as for many different antitumor strategies including chemotherapy, radiotherapy and immunotherapy.⁵ Unfortunately, IFN-based cancer therapy is associated with severe dose-limiting side effects.^{1,2} More recently, activation of endogenous IFN production has been suggested and applied, by means of treatment with Toll-like Receptor (TLR) ligands such as poly(I:C) or CpG oligodeoxynucleotides, or Stimulator of IFN Genes (STING) agonists, either as a primary treatment or to overcome resistance to targeted therapy or immunotherapy.^{18, 38-41} However, also these IFN-inducing strategies are likely to be limited by potential unacceptable toxic side effects.⁴¹⁻⁴⁴ In addition, IFN may not only activate but also suppress anti-cancer immunity.^{1, 18} Therefore, we developed AcTaferons (AFNs), targeting type I IFN activity to selected cell types only, in an attempt to segregate the beneficial from detrimental qualities and side effects of IFN. As targeting modules, we opted for small camelid single domain antibodies, which have superior penetration potential and stability, and are more easily conjugated than conventional antibodies.⁴⁵ In contrast to standard targeted immunocytokines that have been developed over the last decades,⁶ AFNs do not consist of WT cytokines, but instead of a mutated cytokine (type I IFN in this case) with a substantially decreased receptor affinity (IFNAR1 in case of AFNs).¹⁰ As such, AFNs are less active while traveling through the body, and restore their activity at the targeted cell type only. Furthermore, by not interacting with their cognate receptors ubiquitously expressed throughout the body, they will not get trapped or cleared before reaching their target cells,⁸ nor can any interference by soluble receptors occur.

In view of the oncological successes of anti-CD20 targeted therapy, we decided to target AFN to CD20⁺ tumors to obtain proof of concept. Treatment with tumor-targeted AFN drastically reduced lymphoma and melanoma tumor growth without any sign of systemic toxicity, which was evaluated by monitoring body weight and temperature, as well as several blood parameters. Antitumor efficacy depended on the presence of XCR1⁺ cDC1 and CD8⁺ T lymphocytes, and on IFN signaling in conventional DC. Tumor-targeted AFN very efficiently activated both XCR1⁺ and CD11b⁺ conventional DC, and significantly increased effector CTL numbers in lymph nodes and in the tumor, as well as their proliferation in lymph nodes. Importantly, not only mouse CD8⁺ cDC1, but also their CD141⁺ human counterparts, both of which are XCR1⁺, have already been shown to be superior antigen presenting DC, efficiently stimulating both naïve and activated CTL.^{20, 21, 23} In addition, TCGA data analysis has clearly indicated that a high cDC1 signature in the tumor provides the strongest pro-immune survival value across multiple human cancer types, as well as a robust CTL recruiting chemokine profile.^{46, 47} In addition, targeting IFN α as an adjuvant to human DC was recently shown to increase their capacity for antigen presentation and antigen-specific CTL responses to human cancer epitopes.⁴⁸ The antitumor potential of targeting AcTaferons specifically to DC instead of to the tumor microenvironment is currently being explored.

Recently, CD38-targeted attenuated IFN (referred to as an 'Attenukine') was reported to reduce tumor progression in a human multiple myeloma xenograft model in mice.⁴⁹ Importantly, however, this was entirely due to the direct anti-proliferative effect of hIFN on the human tumor cells, as hIFN is not active on mouse cells at all. For the same reason, this study did not allow appropriate assessment of toxic systemic side effects, in contrast to our study.

Tumor-targeted AFN was also very effective to efficiently eradicate tumors in combination treatments with immunogenic chemotherapy or low-dose TNF, again without any toxic adverse effects. This was in sharp contrast with WT mIFN, where combination with chemotherapy or TNF dramatically enhanced toxicity, resulting in mortality due to the treatment. After decades of fruitless immunotherapy attempts,

recent years have shown impressive results of checkpoint inhibition therapy for melanoma, lung cancer and several other tumor types. Nevertheless, many non-immunogenic tumors are still resistant to immunotherapy, and even in the melanoma population less than half of the patients are responsive. On top, about a quarter of the responsive patients develop resistance.⁵⁰ It is generally accepted that modulation of the tumor microenvironment to convert non-immunogenic tumors into immunogenic responders will be key to the further optimization and success rate of checkpoint inhibition therapy.^{15, 18, 32, 51} Interestingly, tumor-targeted AFN was much more effective when combined with PDL1, CTLA4 or LAG3 blockade to shrink and even completely eradicate tumors, again without causing any detectable adverse effects, in contrast with WT IFN or immunocytokine treatments. While B16 tumor growth was slowed down by Treg-depleting anti-CTLA4 plus anti-OX40 treatment, B16 tumors were completely insensitive for the anti-PDL1 or anti-LAG3 monotherapy regime that we applied. Combination of the latter with tumor-targeted AFN therapy, however, efficiently converted the non-responding B16 tumors into responders with full tumor eradication as a result. Therefore, our experiments indicate that targeting type I IFN activity to the tumor, when possible, may represent a very potent and completely safe alternative for systemic treatment with WT IFN or IFN inducers, such as TLR or STING agonists, to convert non-immunogenic neoplasms. In contrast to WT IFN, TLR ligands or STING agonists, AFNs do not provoke any systemic side effects, not even when injected daily in a 4-fold higher dose than presented in this manuscript, either subcutaneously or intravenously (data not shown). In addition, direct effects on tumor cells may also potentially contribute to antitumor efficacy by the release of chemokines.¹⁵ A possible drawback of targeting tumor-associated antigens (TAA) in cancer patients may, however, be on-target off-tumor effects with concomitant toxicity, as is the case for chimeric antigen receptor (CAR) T cell therapy.⁵² Tumors that present tumor-specific antigens (TSA) on their surface, however, could be safely treated without any chance of adverse effects.

306 Although targeting AFN specifically to the tumor cells proved effective to stall tumor growth, the effect of
307 the tumor-targeted AFN did not depend on IFN signaling in the tumor cells themselves. This may indicate
308 that enhanced localization of AFN in the tumor niche suffices to mount an efficient antitumor immune
309 response, which may involve signaling in the DCs that we identified using the CD11c-IFNAR-deficient mice.
310 Furthermore, although we chose CD20 as a targeting strategy, the antitumor efficacy of CD20-targeted
311 AFN did not depend on B lymphocytes either. In contrast, the antitumor effect of tumor-targeted AFN
312 clearly relied on the presence of XCR1⁺ conventional DC as well as on IFN signaling in conventional DC.
313 Hence, we conclude that the completely safe and highly efficient antitumor effect of tumor-targeted type
314 I IFN activity critically requires IFN signaling in the XCR1⁺ conventional DC locally present in the tumor
315 microenvironment. Of interest, these conventional DC have already been described to require type I IFN
316 signaling to efficiently present tumor antigen to tumor-killing CTL.^{19, 22}

Figure legends

Figure 1. mCD20-AcTaferon proof-of-principle. (A) General lay-out of an AcTaferon (AFN). The hIFN α 2-Q124R, human IFN α 2 with a Q124R point mutation, active on mouse cells but at a 100-fold lower level than murine IFN, is coupled to a sdAb module recognizing mCD20, hCD20, GFP or Bcl110 via a GGS linker molecule. (B) Phospho-STAT1 as a read-out for IFN signaling in spleen CD19⁺ B lymphocytes isolated from mice treated 45 min earlier with i.v. PBS, serial dilutions of B cell targeted mCD20-AFN or untargeted GFP-AFN. (C) Proliferation of A20 cells treated *in vitro* for 72 hours with serial dilutions of mCD20-AFN or GFP-AFN. Results are expressed as percentage of cells versus untreated culture. (D) Growth of s.c. inoculated A20 tumors in syngeneic Balb/c mice after treatments with PBS, mCD20-mIFN (immunocytokine) or hCD20-mIFN (untargeted mIFN), mCD20-AFN (= targeted), hCD20-AFN (untargeted control) or mCD20-hIFN ("sdAb-only" control). Arrows indicate treatment days, starting at day 6 after tumor inoculation. Shown is a representative experiment. Error bars represent mean \pm s.e.m.; *** P <0.001 and **** P <0.0001 compared with PBS treated animals by two-way ANOVA with Dunnett's multiple comparison test (n=5 mice per group).

Figure 2. Targeted AcTaferon delivery to B16 tumors controls tumor growth without toxicity. (A) Growth of s.c. inoculated B16-mCD20⁺ tumors in syngeneic C57BL/6J mice after treatments with PBS, mCD20-mIFN (immunocytokine) or hCD20-mIFN (untargeted mIFN), mCD20-AFN (targeted) or hCD20-AFN (untargeted), or mCD20-hIFN as a negative control for "sdAb-only" effects. Shown is a representative experiment of 7 independent repeats (n=5 mice per group), arrows indicate treatment days. (B) Seven independent experiments were pooled to plot the time necessary for each mouse to reach a tumor of 70 mm² (total n = indicated in the legend). (C) Body weight changes of tumor-bearing mice treated with mCD20-targeted mIFN or AFN (n=5). (D-I) Hematological analyses (platelet counts, mean platelet volume,

red blood cell, neutrophil, monocyte and lymphocyte counts) in fresh EDTA-blood collected 1 day after the last treatment. 'Naive mice' are tumor-free, 'tumor mice' are tumor-bearing treated with PBS. All values depicted are mean \pm s.e.m.; * P <0.05, ** P <0.01, *** P <0.001 and **** P <0.0001 compared with PBS treated animals unless otherwise indicated; by two-way ANOVA with Dunnett's multiple comparison test (A, C), one-way ANOVA with Dunnett's multiple comparison test (D-I) or log-rank test (B). Shown are representative results of 7 independent repeats (C-I).

Figure 3. Partial lymphopenia due to mCD20-AcTaferon therapy is not required for antitumor efficacy.

(A) Growth of s.c. inoculated B16-mCD20⁺ tumors in C57BL/6J mice after treatments with PBS, or different doses of mCD20-mIFN or mCD20-AFN. Shown is a representative experiment of 2 independent repeats (n=5 mice per group). (B-D) Lymphocyte, neutrophil and platelet counts in fresh EDTA-blood collected 1 day after the last treatment. 'Naive mice' are tumor-free. All values depicted are mean \pm s.e.m.; * P <0.05, ** P <0.01 compared with PBS treated animals, by two-way ANOVA with Dunnett's multiple comparison test (A), or one-way ANOVA with Dunnett's multiple comparison test (B-D).

Figure 4. Antitumor efficacy of tumor-targeted AcTaferon depends on cDC1 and CTL.

(A) Growth of B16-mCD20⁺ tumors in IFNAR1-deficient versus WT mice after 7 treatments with PBS or tumor-targeted mIFN or AFN (n=5 mice per group). (B) Growth of B16-mCD20⁺ or B16-mCD20⁺-IFNAR^{-/-} tumors in WT mice after 10 treatments with PBS or tumor-targeted AFN (n=12 mice per group, pooled results of 2 different IFNAR^{-/-} B16-mCD20⁺ clones). (C) Growth of s.c. inoculated B16-hCD20⁺ tumors in C57BL/6J mice after treatments with PBS, hCD20-AFN or mCD20-AFN. Shown is a representative experiment (n=5 mice per group). (D) Lymphocyte counts in fresh EDTA-blood collected 1 day after the last treatment of mice represented in C. 'Naive mice' are tumor-free. (E) Growth of B16-mCD20⁺ tumors in Batf3^{-/-} mice (lacking cDC1) and WT

littermates after 6 treatments with PBS or mCD20-AFN (n=7 mice per group). **(F)** Growth of B16-mCD20⁺ tumors in CD11c-IFNAR-deficient mice (lacking IFNAR in cDC1 and cDC2) and WT littermates after 5 treatments (n=4 mice per group). **(G)** Growth of B16-mCD20⁺ tumors in CD8-depleted mice and controls after 6 treatments (n=5 mice per group). **(H)** Growth of B16-mCD20⁺ tumors in CD4-IFNAR-deficient mice (lacking IFNAR in T lymphocytes) and WT littermates after 5 treatments (n=4 mice per group). All results shown are a representative of two independent repeats. Shown are mean \pm s.e.m. * P <0.05, ** P <0.01, *** P <0.001 and **** P <0.0001 compared with PBS treated animals unless otherwise indicated; determined by two-way ANOVA with Dunnett's multiple comparison test.

Figure 5. DC and CTL responses during AcTaferon treatments. **(A)** Flow cytometric profiling of the DC activation status in the tumor draining lymph node in response to AFN treatment. DCs were identified as CD3⁻ CD19⁻ Ly6C⁻ CD11c^{int-hi} MHCII^{int-hi} cells and subdivided into XCR1⁺ cDC1 and CD11b⁺ cDC2. Expression levels of PDL1, MHCII, CD80, CD86 and CD40 are displayed as MFI in the respective fluorescence channels. Results shown are a representative of two independent repeats (n=5). **(B)** Flow cytometric analysis of CD3⁺ CD8⁺ T cell phenotype based on the expression of CD44 and CD62L was performed on tumor-draining lymph nodes of mice bearing B16 tumors, five days after perilesional delivery of the AFNs indicated in the figure legend (n=3). Effector T cells were identified as CD44 high and CD62L low. **(C)** Flow cytometric analysis of Pmel-1 T cell proliferation in the tumor-draining lymph node in response to perilesional AFN treatment of B16-mCD20 tumor-bearing mice. Data show the percentage of T cells having undergone at least one division. **(D-E)** Flow cytometric analysis of CD3⁺ CD8⁺ T cell phenotype based on the expression of CD44 and CD62L was performed on B16 tumors, five days after perilesional delivery of the AFNs indicated in the figure legend (n=3). Naive cells **(D)** were identified as CD44 low and CD62L high, effector T cells **(E)** as CD44 high and CD62L low. Shown are individual values **(A)** and mean \pm s.e.m. of a representative experiment of at least 2 independent repeats **(A-E)**; * P <0.05, ** P <0.01, *** P <0.001 and

**** $P < 0.0001$ compared with PBS treated animals unless otherwise indicated; by one-way ANOVA with Tukey's multiple comparison test.

Figure 6. Tumor-targeted AcTaferon combination treatments eradicate tumors without toxicity. (A)

Growth of s.c. inoculated B16-mCD20⁺ tumors in C57BL/6J mice, body weight loss (B), neutrophil counts (C) and mortality (D) after 8 treatments with PBS, tumor-targeted mCD20-mIFN or mCD20-AFN (n=5 mice per group, shown is a representative experiment, arrows indicate treatment days). When indicated in the legends, tumors were also treated with doxorubicin every second day. (E) Growth of s.c. inoculated B16-mCD20⁺ tumors in C57BL/6J mice, body weight loss (F), platelet counts (G) and mortality (H) after 8 treatments with PBS, tumor-targeted mCD20-mIFN or mCD20-AFN (n=5 mice per group, shown is a representative experiment, arrows indicate treatment days). When indicated in the legends, tumors were also treated with low-dose (0.6 µg/mouse) TNF every second day. (I-K) Growth of s.c. inoculated B16-mCD20⁺ tumors in C57BL/6J mice treated with PBS or mCD20-AFN. When indicated, treatment was combined with anti-PDL1 sdAb or a combination of Treg-depleting (TregΔ) anti-CTLA4 + anti-OX40 antibodies. Dividend/divisor in the figures indicates the number of tumor-free mice over the number of total mice at the day the experiment was ended, indicated in the X axis. For all figures, a representative experiment is shown (n=4-6 per group), repeated at least twice. All values are mean ± s.e.m.; * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ and **** $P < 0.0001$ compared with PBS treated animals unless otherwise indicated; by two-way ANOVA with Dunnett's multiple comparison test (A-B, E-F, I-K), one-way ANOVA with Dunnett's multiple comparison test (C, G) or log-rank test (D, H).

Figure 7. Tumor-targeted AcTaferon therapy provides immunity. (A)

Growth of s.c. inoculated B16-mCD20⁺ tumors in naive C57BL/6J mice. (B) Growth of B16-mCD20⁺ tumors inoculated on the contralateral

flank on day 35 in mice where complete eradication of the primary tumor was achieved thanks to specific treatments (day 7-17) indicated in the figure legend. Tumor growth was evaluated for 60 days after the second tumor inoculation. **(C)** Growth of s.c. inoculated B16-mCD20⁺ tumors in naive C57BL/6J mice, or in mice where the primary tumor was treated with PBS (day 5-10). **(D)** Growth of B16-mCD20⁺ tumors inoculated on the contralateral flank on day 12 in mice that received p.l. treatment for their primary tumor with mCD20-AFN on days 5-10. The experiment was ended 14 days after the second tumor inoculation (26 days after the primary tumor inoculation). Tumor growth of individual mice are plotted, the number of mice that remained tumor-free for the duration of the experiment (60 days for **A-B** and 14 days for **C-D**) is indicated in each figure.

Experimental procedures

Construction and production of AcTaferons and immunocytokines

The mutation Q124R was introduced into the IFN α 2 sequence by site-directed mutagenesis using the QuikChange II-E Site-Directed Mutagenesis Kit (Agilent Technologies) and single domain llama VHH antibodies (sdAb) were generated at the VIB Protein Service Facility, as described previously¹⁰. Mouse AcTaferons are composed of hIFN α 2Q124R⁹ coupled via a 20xGGG-linker to an N-terminal targeting sdAb. A C-terminal tag is added for easy purification. AcTaferons and immunocytokines (WT mIFN α 11 coupled to sdAb) were constructed in pHen6 vectors, large scale productions of His-tagged AcTaferons were performed in *E. coli*. The bacteria were cultured till stationary phase (OD₆₀₀ of 0.7-0.8) whereupon IPTG (BioScientific) was added to activate the LacZ promoter. Cell supernatant was collected after overnight culture. The proteins in the periplasmic fraction were released by osmotic shock using a sucrose solution and were purified by immobilized metal ion chromatography (IMAC) on a HiTrap Sepharose resin loaded with Kobalt ions (Clontech, Takara Biotechnology). After binding of the protein, columns were washed with 0.5% EMPIGEN (Calbiochem, Millipore), 0.5% CHAPS (Sigma-Aldrich) and PBS. Imidazole (Merck) was used for elution and removed using PD-10 gel filtration columns (GE Healthcare). Protein concentration was determined using the absorbance at 280 nm and purity was assessed via SDS-PAGE. LPS levels were quantified using Limulus Amebocyte Lysate (LAL) QCL-1000 (Lonza). If still present, LPS was removed using Endotoxin Removal Resin (Thermo Scientific). Biological activities of all products were assessed by a functional assay using the mouse luciferase reporter cell line LL171 against the WHO International mouse IFN α standard Ga02-901-511 as described previously¹⁰.

Mice, cells and tumor models

442 Mice were maintained in pathogen-free conditions in a temperature-controlled environment with 12/12
 443 hour light/dark cycles and received food and water *ad libitum*. Animal experiments followed the
 444 Federation of European Laboratory Animal Science Association (FELASA) guidelines and were approved
 445 by the Ethical Committee of Ghent University. Female C57BL/6J and Balb/c mice (Charles River
 446 Laboratories, Saint-Germain sur l'Arbresle, France) were inoculated at the age of 7-10 weeks. For
 447 experiments using knock-out mice (IFNAR1, Batf3), mice were bred in our own facilities and WT
 448 littermates were used as controls. For s.c. tumor models, cells were injected using a 30G insulin syringe,
 449 in 50 μ l suspension, on the shaved flank of briefly sedated mice (using 4% isoflurane). For the s.c. A20
 450 lymphoma model, $5 \cdot 10^6$ cells were inoculated; for the B16-mCD20 and B16-hCD20 clones $6 \cdot 10^5$ cells. The
 451 B16-mCD20 and B16-hCD20 cell lines were generated as follows: B16Bl6 cells were stably co-transfected
 452 with a plasmid containing the expression cassettes for mCD20 or hCD20, and with a plasmid containing
 453 the neomycin resistance gene. Stable transfected cells were selected with G418 (2 mg/ml)-containing
 454 medium, followed by FACS sorting of mCD20- or hCD20-expressing cells. From the pool of hCD20 and
 455 mCD20 expressing B16-Bl6 cells, single clones were selected by limited dilution. The B16-mCD20-IFNAR1^{-/-}
 456 cell lines were generated via the CRISPR-Cas9 editing system, using 2 different gRNA sequences targeting
 457 exon 2 of IFNAR1, 5'-AGCAGCCACGGAGAGTCAAT-3' and 5'-ATGTAGACGTCTATATTCTC-3' (determined via
 458 <http://crispr.mit.edu>). The gRNA were cloned in the pSpCas9(BB)-2A-Puro vector (PX459)⁵³ and
 459 transfected into B16-mCD20 cells via Jetprime. After 4 weeks of selection with 1 μ g/ml puromycine,
 460 negative selection of the 2 different cell pools was performed using MACS with anti-IFNAR1-PE
 461 (eBioScience) and anti-PE microbeads (Miltenyi Biotec). The absence of IFNAR1 was verified with flow
 462 cytometry (evaluating mIFNAR1 presence using anti-IFNAR1-PE) as well as functionally determining P-
 463 STAT1 signaling 15 and 30 min after mIFN treatment. Cell lines were purchased from American Type
 464 Culture Collection and cultured in conditions specified by the manufacturer. All cells used for inoculation
 465 were free of mycoplasma. Tumor diameters were measured using a caliper. To analyze tumor immunity,

mice were re-challenged on the contralateral flank with a new dose of tumor cells. Re-challenge was done either on tumor-free mice (after successful therapy), or on tumor-bearing mice after a short 6 day treatment schedule (day 5-10). Before the start of the treatments, mice were randomly and blindly allocated to a therapy group, the size of the groups was determined by the number of mice available with an appropriate tumor size; we strived to have at least 5 animals per experimental group. To determine clear-cut unambiguous antitumor effect, we know from experience that 5 animals suffice to obtain statistical significance. Monotherapy experiments were performed in at least 7 individual experiments, combination therapies in at least 2. Data were normally distributed, variance between groups was not significantly different. Differences in measured variables between the experimental and control group were assessed by using one-way or two-way ANOVA followed by Dunnett's or Tukey's multiple-comparison test. Survival curves were compared using the log-rank test. GraphPad Prism software was used for statistical analysis.

Tumor treatments

Unless otherwise indicated, tumor treatments were done perilesionally (p.l.), which is s.c. at the tumor border. As a control, mice were always treated with PBS. AcTaferons were given at 5,500 IU per treatment, WT mIFN or immunocytokine at $\sim 5\text{-}9 \cdot 10^6$ unless noted otherwise in the figure legend. These treatment doses corresponded to $\sim 30 \mu\text{g}$ protein (1.4 mg/kg). For combination therapies, we injected doxorubicine (3 mg/kg), rmTNF (28 $\mu\text{g/kg}$), anti-PDL1 sdAb (5.5 mg/kg), anti-CTLA4 Ab (450 $\mu\text{g/kg}$), anti-OX40 Ab (1.8 mg/kg), anti-LAG3 Ab (9 mg/kg). These were not injected daily, but every 2-3 days.

In vitro proliferation assays

A20 cells were cultured at 100,000 cells/ml in 25 cm² cell culture flasks. Serial dilutions of mCD20-AcTaferon or GFP-AcTaferon were added and 72 hours later cells were counted by using a Scepter cell counter (Millipore). Results are expressed as percentage of A20 cells versus untreated culture (considered as the 100%). B16-mCD20 cells were cultured at 1,000 cells/well in a 96 well plate, and incubated with medium, mCD20-mIFN or mCD20-targeted or hCD20-untargeted AcTaferon for 24 hours. Cell proliferation was evaluated using the CellTiter-Glo[®] Luminescent Cell Viability Assay (Promega).

Inhibitors, antibodies and checkpoint blockades

To inhibit the immune modulating PD1-PDL1 pathway, mice were treated with a neutralizing anti-PDL1 sdAb (120 µg/mouse), given i.p. every second day. To block CTLA4 signaling and deplete intratumoral regulatory T cells⁵⁴, we used anti-CTLA4 (10 µg/mouse, BioXCell clone 9H10) and anti-OX40 (40 µg/mouse, BioXCell clone OX-86) given 3x/week. Anti-LAG3 (200 µg/mouse, BioXCell clone C9B7W) was given in the same schedule. Depletion of CD8⁺ cells was performed by i.p. administration of 200 µg rat-anti-mouse CD8 Ab (BioXCell clone YTS169.4) one day prior to the first AcTaferon treatment. Additional depletion rounds were performed 4 and 10 days after the first. Control (non-depleted) mice were treated with 200 µg rat IgG2b Isotype Control Ab (BioXCell clone LTF-2). CD8⁺ cell depletion was evaluated with flow cytometry on blood, spleen, lymph nodes and tumor, as well as via IHC on spleen and tumor. Depletion was observed as soon as 4 hours after Ab injection and lasted at least 4 days. Thanks to additional depletion round CD8⁺ cells were absent during the entire AFN treatment period.

Flow cytometry analysis and sorting

For *ex vivo* P-STAT1 signaling analysis, different amounts of mCD20-AcTaferon or GFP-AcTaferon or mCD20-hIFN-R149A were injected intravenously through the retro-orbital vein in Balb/c mice (female, 14 weeks) and spleens were recovered 45 minutes later. Splenocytes were isolated, fixed, permeabilized and labelled with anti-CD19-APC and anti-phospho-Stat1-PE antibodies (BD Biosciences)¹⁰. Samples were acquired on a FACS Canto (BD Biosciences) and data were analyzed using DIVA software (BD Biosciences). For analysis of CD19⁺ B, CD4⁺ and CD8⁺ T cell populations in circulation, blood was collected from the tail vein with a heparinized capillary and stained for flow cytometric analysis using CD19, CD4 or CD8 antibodies (CD19 FITC, BD; CD4 APC, Immunotools; CD8a PE, eBioScience). PDL1 expression was analyzed on B16-mCD20 cells *in vitro* after 48h, and *in vivo* (spleen + tumor) after 24h.

Analysis of the DC activation status

To address the impact of perilesional AFN treatment on the DC activation status in the tumor draining lymph node, B16-mCD20 melanoma bearing mice were injected with BCII10-AFN, mCD20-AFN (5000 IU) or PBS. 24 hours post injection, tumor-draining lymph nodes were dissected and processed for flow cytometry. Cell suspensions were stained with CD16/CD32 to block Fc receptors, followed by CD3-AlexaFluor-700, CD19-AlexaFluor-700, Ly6C-PECy7, CD11b-APCCy7, CD86-eFluor450, PDL1-PE, CD40-APC, CD80-APC, CD11c-PEeFluor610, MHCI-FITC (all eBioscience), XCR1-BV650 (BioLegend). After exclusion of T and B cells and Ly6C^{hi} monocytes, DCs were identified based on their expression of CD11c and MHCII. XCR1⁺ cDC1s were identified based on their XCR1⁺ CD11b⁻ MHCII^{int-hi} CD11c^{int-hi} phenotype, whereas CD11b⁺ cDC2s were identified based on their XCR1⁻ CD11b⁺ MHCII^{int-hi} CD11c^{int-hi} phenotype. Samples were acquired on a BD LSR Fortessa (5-laser) and analyzed using FlowJo software.

Analysis of CTL proliferation and activation

To analyze activated T cell phenotype, tumor draining lymph nodes were dissected at different time points after single perilesional delivery of AcTaferons and processed for flow cytometry. Fc receptors were blocked using CD16/CD32, whereupon single cell suspensions were stained with CD3-PeCy7 (clone 145-2C11), CD4-PE (clone RMA-5), CD8-APC (clone 53-6.7) (all BD Pharmingen), CD44-PercP-Cy5.5 (clone IMF7) and CD62L-APC-Cy7 (clone MEL-14) (both BioLegend). Effector T cells were identified based on their CD44^{hi}CD62L^{low} phenotype. Samples were acquired on an Attune NxT Acoustic Focusing Cytometer (Life Technologies) and analyzed using FlowJo software. To evaluate CTL proliferation, we used T cell receptor transgenic CD8⁺ T cells specifically recognizing the melanocyte differentiation antigen gp100 (Pmel-1) present on B16 tumor cells. Gp100-specific CD8 Pmel-1 T cells were isolated from the spleens of C57BL/6J Pmel-1–Thy1.1 mice, using the CD8 α ⁺ T Cell Isolation Kit (Miltenyi Biotec) and labeled with 5 μ M of CFSE (Thermo Fisher). One million of CFSE-labeled T cells were adoptively transferred to C57BL/6 mice inoculated with 6.10⁵ B16 melanoma cells. Subsequently, mice were treated with the indicated AcTakines. At least five days post adoptive T cell transfer, tumor-draining lymph nodes and spleen were dissected and specific T cell proliferation was assessed by Flow Cytometry. Samples were acquired on a BD LSR Fortessa (5-laser) or on an Attune NxT Acoustic Focusing Cytometer (Life Technologies) and analyzed using FlowJo software.

Hematological analysis

One day after the last tumor treatment, blood was collected from the tail vein in EDTA-coated microvette tubes (Sarstedt), and analyzed in a Hemavet 950FS (Drew Scientific, Waterbury, USA) whole blood counter.

Disclosure of potential conflict of interest

J.T. and G.U. are scientific co-founders, and J.T. is CTO of Orionis Biosciences and holds stock-options in the company.

Acknowledgements

We thank Johan Grooten for the anti-PDL1 sdAb, Reza Hassanzadeh Ghassabeh (VIB Nanobody Core) for the selection of the anti-CD20 sdAbs, Claude Libert for the IFNAR1^{-/-} mice, Veronique Flamand for the Batf3^{-/-} mice, Ulrich Kalinke for CD11c-IFNAR- and CD4-IFNAR-deficient mice, Feng Zhang for the PX459 vector.

Funding

This work was supported by UGent Methusalem and Advanced ERC (CYRE, N° 340941) grants to J.T.; an FWO-V grant G009614N to J.T. and S.G.; grants from LabEx MablImprove, Institut Carnot CALYM, the Canceropôle - Institut National du Cancer (INCa) to G.U.; the SIRIC Montpellier Cancer INCa-DGOS-Inserm 6045 to F.P.; and by Orionis Biosciences.

Author contributions

A.C. and J.T. designed experiments and analyzed and interpreted the data. A.C., S.V.L., G.G., J.v.D.H. conducted experiments. D.C., E.R. and A.V. provided technical support, including construction and purification and help with animal work. J.B. made the stable mCD20- and hCD20-B16 clones, L.D.C. the B16-mCD20-IFNAR1^{-/-} clones, and S.G. helped with AcTaferon designs. G.U. designed and supervised the work proving the cell-targeting efficacy, performed by F.P. and Y.B. A.C., G.U. and J.T. wrote the manuscript.

578 **References**

- 579 1. Jonasch E and Haluska FG. Interferon in oncological practice: review of interferon biology, clinical
580 applications, and toxicities. *Oncologist*. 2001;6:34-55.
- 581 2. Kirkwood JM, Bender C, Agarwala S, Tarhini A, Shipe-Spotloe J, Smelko B, Donnelly S and Stover
582 L. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. *J Clin*
583 *Oncol*. 2002;20:3703-18.
- 584 3. Parker BS, Rautela J and Hertzog PJ. Antitumour actions of interferons: implications for cancer
585 therapy. *Nat Rev Cancer*. 2016;16:131-44.
- 586 4. Belardelli F and Gresser I. The neglected role of type I interferon in the T-cell response:
587 implications for its clinical use. *Immunol Today*. 1996;17:369-72.
- 588 5. Zitvogel L, Galluzzi L, Kepp O, Smyth MJ and Kroemer G. Type I interferons in anticancer immunity.
589 *Nat Rev Immunol*. 2015;15:405-14.
- 590 6. List T and Neri D. Immunocytokines: a review of molecules in clinical development for cancer
591 therapy. *Clin Pharmacol*. 2013;5:29-45.
- 592 7. Rossi EA, Goldenberg DM, Cardillo TM, Stein R and Chang CH. CD20-targeted tetrameric
593 interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas. *Blood*.
594 2009;114:3864-71.
- 595 8. Tzeng A, Kwan BH, Opel CF, Navaratna T and Wittrup KD. Antigen specificity can be irrelevant to
596 immunocytokine efficacy and biodistribution. *Proc Natl Acad Sci U S A*. 2015;112:3320-5.
- 597 9. Weber H, Valenzuela D, Lujber G, Gubler M and Weissmann C. Single amino acid changes that
598 render human IFN-alpha 2 biologically active on mouse cells. *EMBO J*. 1987;6:591-8.
- 599 10. Garcin G, Paul F, Staufienbiel M, Bordat Y, Van der Heyden J, Wilmes S, Cartron G, Apparailly F, De
600 Koker S, Piehler J, Tavernier J and Uze G. High efficiency cell-specific targeting of cytokine activity. *Nat*
601 *Commun*. 2014;5:3016.
- 602 11. De Groeve K, Deschacht N, De Koninck C, Caveliers V, Lahoutte T, Devoogdt N, Muyldermans S,
603 De Baetselier P and Raes G. Nanobodies as tools for in vivo imaging of specific immune cell types. *J Nucl*
604 *Med*. 2010;51:782-9.
- 605 12. Trinh KR, Vasuthasawat A, Steward KK, Yamada RE, Timmerman JM and Morrison SL. Anti-CD20-
606 interferon-beta fusion protein therapy of murine B-cell lymphomas. *J Immunother*. 2013;36:305-18.
- 607 13. Lechner MG, Karimi SS, Barry-Holson K, Angell TE, Murphy KA, Church CH, Ohlfest JR, Hu P and
608 Epstein AL. Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and
609 response to immunotherapy. *J Immunother*. 2013;36:477-89.
- 610 14. Overwijk WW and Restifo NP. B16 as a mouse model for human melanoma. *Curr Protoc Immunol*.
611 2001;Chapter 20:Unit 20 1.
- 612 15. Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE,
613 Remedios C, Fend L, Hannani D, Aymeric L, Ma Y, Niso-Santano M, Kepp O, Schultze JL, Tuting T, Belardelli
614 F, Bracci L, La Sorsa V, Ziccheddu G, Sestili P, Urbani F, Delorenzi M, Lacroix-Triki M, Quidville V, Conforti
615 R, Spano JP, Pusztai L, Poirier-Colame V, Delaloge S, Penault-Llorca F, Ladoire S, Arnould L, Cyrta J,
616 Dessoliers MC, Eggermont A, Bianchi ME, Pittet M, Engblom C, Pfirschke C, Preville X, Uze G, Schreiber RD,
617 Chow MT, Smyth MJ, Proietti E, Andre F, Kroemer G and Zitvogel L. Cancer cell-autonomous contribution
618 of type I interferon signaling to the efficacy of chemotherapy. *Nat Med*. 2014;20:1301-9.
- 619 16. Chen DS and Mellman I. Oncology meets immunology: the cancer-immunity cycle. *Immunity*.
620 2013;39:1-10.
- 621 17. Schlitzer A and Ginhoux F. Organization of the mouse and human DC network. *Curr Opin Immunol*.
622 2014;26:90-9.

- 623 18. Minn AJ and Wherry EJ. Combination Cancer Therapies with Immune Checkpoint Blockade:
624 Convergence on Interferon Signaling. *Cell*. 2016;165:272-5.
- 625 19. Diamond MS, Kinder M, Matsushita H, Mashayekhi M, Dunn GP, Archambault JM, Lee H, Arthur
626 CD, White JM, Kalinke U, Murphy KM and Schreiber RD. Type I interferon is selectively required by
627 dendritic cells for immune rejection of tumors. *J Exp Med*. 2011;208:1989-2003.
- 628 20. Bachem A, Guttler S, Hartung E, Ebstein F, Schaefer M, Tannert A, Salama A, Movassaghi K, Opitz
629 C, Mages HW, Henn V, Kloetzel PM, Gurka S and Kroczek RA. Superior antigen cross-presentation and
630 XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. *J Exp*
631 *Med*. 2010;207:1273-81.
- 632 21. Crozat K, Guiton R, Contreras V, Feuillet V, Dutertre CA, Ventre E, Vu Manh TP, Baranek T, Storset
633 AK, Marvel J, Boudinot P, Hosmalin A, Schwartz-Cornil I and Dalod M. The XC chemokine receptor 1 is a
634 conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells. *J Exp*
635 *Med*. 2010;207:1283-92.
- 636 22. Fuertes MB, Kacha AK, Kline J, Woo SR, Kranz DM, Murphy KM and Gajewski TF. Host type I IFN
637 signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. *J Exp Med*.
638 2011;208:2005-16.
- 639 23. Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, Chen CJ, Dunbar PR, Wadley
640 RB, Jeet V, Vulink AJ, Hart DN and Radford KJ. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a
641 unique myeloid DC subset that cross-presents necrotic cell antigens. *J Exp Med*. 2010;207:1247-60.
- 642 24. Hildner K, Edelson BT, Purtha WE, Diamond M, Matsushita H, Kohyama M, Calderon B, Schraml
643 BU, Unanue ER, Diamond MS, Schreiber RD, Murphy TL and Murphy KM. Batf3 deficiency reveals a critical
644 role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. *Science*. 2008;322:1097-100.
- 645 25. Lejeune FJ. Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing
646 vascular permeability. *J Clin Invest*. 2002;110:433-5.
- 647 26. van Horssen R, Ten Hagen TL and Eggermont AM. TNF-alpha in cancer treatment: molecular
648 insights, antitumor effects, and clinical utility. *Oncologist*. 2006;11:397-408.
- 649 27. Topalian SL, Drake CG and Pardoll DM. Immune checkpoint blockade: a common denominator
650 approach to cancer therapy. *Cancer Cell*. 2015;27:450-61.
- 651 28. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R,
652 Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I,
653 McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt
654 L, Yang A, Rollin LM, Horak C, Hodi FS and Wolchok JD. Combined Nivolumab and Ipilimumab or
655 Monotherapy in Untreated Melanoma. *N Engl J Med*. 2015;373:23-34.
- 656 29. Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN, Weichselbaum RR, Fu YX and Auh SL. The
657 efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive
658 immunity. *Cancer Res*. 2011;71:2488-96.
- 659 30. Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, Li XD, Mauceri H, Beckett M, Darga T, Huang
660 X, Gajewski TF, Chen ZJ, Fu YX and Weichselbaum RR. STING-Dependent Cytosolic DNA Sensing Promotes
661 Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. *Immunity*.
662 2014;41:843-52.
- 663 31. Woo SR, Fuertes MB, Corrales L, Spranger S, Furdyna MJ, Leung MY, Duggan R, Wang Y, Barber
664 GN, Fitzgerald KA, Alegre ML and Gajewski TF. STING-dependent cytosolic DNA sensing mediates innate
665 immune recognition of immunogenic tumors. *Immunity*. 2014;41:830-42.
- 666 32. Bald T, Landsberg J, Lopez-Ramos D, Renn M, Glodde N, Jansen P, Gaffal E, Steitz J, Tolba R, Kalinke
667 U, Limmer A, Jonsson G, Holzel M and Tuting T. Immune cell-poor melanomas benefit from PD-1 blockade
668 after targeted type I IFN activation. *Cancer Discov*. 2014;4:674-87.
- 669 33. Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ,
670 Rodig SJ, Asahina H, Jones RE, Kulkarni MM, Kuraguchi M, Palakurthi S, Fecci PE, Johnson BE, Janne PA,

- Engelman JA, Gangadharan SP, Costa DB, Freeman GJ, Bueno R, Hodi FS, Dranoff G, Wong KK and Hamerman PS. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. *Nat Commun*. 2016;7:10501.
34. Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma DA, Xu X, Feldman MD, Gangadhar TC, Hahn SM, Wherry EJ, Vonderheide RH and Minn AJ. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. *Nature*. 2015;520:373-7.
35. Marabelle A, Kohrt H and Levy R. New insights into the mechanism of action of immune checkpoint antibodies. *Oncoimmunology*. 2014;3:e954869.
36. He Y, Rivard CJ, Rozeboom L, Yu H, Ellison K, Kowalewski A, Zhou C and Hirsch FR. Lymphocyte-activation gene-3, an important immune checkpoint in cancer. *Cancer Sci*. 2016;107:1193-7.
37. Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, Diamond MS, Koebel CM, Arthur C, White JM and Schreiber RD. A critical function for type I interferons in cancer immunoediting. *Nat Immunol*. 2005;6:722-9.
38. Dahal LN, Dou L, Hussain K, Liu R, Earley A, Cox KL, Murinello S, Tracy I, Forconi F, Steele AJ, Duriez PJ, Gomez-Nicola D, Teeling JL, Glennie MJ, Cragg MS and Beers SA. STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy. *Cancer Res*. 2017;77:3619-3631.
39. Fu J, Kanne DB, Leong M, Glickman LH, McWhirter SM, Lemmens E, Mechette K, Leong JJ, Lauer P, Liu W, Sivick KE, Zeng Q, Soares KC, Zheng L, Portnoy DA, Woodward JJ, Pardoll DM, Dubensky TW, Jr. and Kim Y. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. *Sci Transl Med*. 2015;7:283ra52.
40. Li K, Qu S, Chen X, Wu Q and Shi M. Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways. *Int J Mol Sci*. 2017;18.
41. Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, Woo SR, Lemmens E, Banda T, Leong JJ, Metchette K, Dubensky TW, Jr. and Gajewski TF. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. *Cell Rep*. 2015;11:1018-30.
42. Sparwasser T, Miethke T, Lipford G, Borschert K, Hacker H, Heeg K and Wagner H. Bacterial DNA causes septic shock. *Nature*. 1997;386:336-7.
43. Stevenson HC, Abrams PG, Schoenberger CS, Smalley RB, Herberman RB and Foon KA. A phase I evaluation of poly(I,C)-LC in cancer patients. *J Biol Response Mod*. 1985;4:650-5.
44. Sparwasser T, Koch ES, Vabulas RM, Heeg K, Lipford GB, Ellwart JW and Wagner H. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. *Eur J Immunol*. 1998;28:2045-54.
45. Wesolowski J, Alzogaray V, Reyelt J, Unger M, Juarez K, Urrutia M, Cauerhff A, Danquah W, Rissiek B, Scheuplein F, Schwarz N, Adriouch S, Boyer O, Seman M, Licea A, Serreze DV, Goldbaum FA, Haag F and Koch-Nolte F. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. *Med Microbiol Immunol*. 2009;198:157-74.
46. Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, Barczak A, Rosenblum MD, Daud A, Barber DL, Amigorena S, Van't Veer LJ, Sperling AI, Wolf DM and Krummel MF. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. *Cancer Cell*. 2014;26:638-52.
47. Spranger S, Dai D, Horton B and Gajewski TF. Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. *Cancer Cell*. 2017;31:711-723 e4.
48. Graham JP, Authie P, Karolina Palucka A and Zurawski G. Targeting interferon-alpha to dendritic cells enhances a CD8+ T cell response to a human CD40-targeted cancer vaccine. *Vaccine*. 2017;35:4532-4539.

- 719 49. Pogue SL, Taura T, Bi M, Yun Y, Sho A, Mikesell G, Behrens C, Sokolovsky M, Hallak H, Rosenstock
720 M, Sanchez E, Chen H, Berenson J, Doyle A, Nock S and Wilson DS. Targeting Attenuated Interferon-alpha
721 to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target
722 Activity. *PLoS One*. 2016;11:e0162472.
- 723 50. Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber
724 JS, Gangadhar TC, Hersey P, Dronca R, Joseph RW, Zarour H, Chmielowski B, Lawrence DP, Algazi A, Rizvi
725 NA, Hoffner B, Mateus C, Gergich K, Lindia JA, Giannotti M, Li XN, Ebbinghaus S, Kang SP and Robert C.
726 Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced
727 Melanoma. *JAMA*. 2016;315:1600-9.
- 728 51. Bezu L, Gomes-de-Silva LC, Dewitte H, Breckpot K, Fucikova J, Spisek R, Galluzzi L, Kepp O and
729 Kroemer G. Combinatorial strategies for the induction of immunogenic cell death. *Front Immunol*.
730 2015;6:187.
- 731 52. Bonifant CL, Jackson HJ, Brentjens RJ and Curran KJ. Toxicity and management in CAR T-cell
732 therapy. *Mol Ther Oncolytics*. 2016;3:16011.
- 733 53. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA and Zhang F. Genome engineering using the
734 CRISPR-Cas9 system. *Nat Protoc*. 2013;8:2281-2308.
- 735 54. Marabelle A, Kohrt H, Sagiv-Barfi I, Ajami B, Axtell RC, Zhou G, Rajapaksa R, Green MR, Torchia J,
736 Brody J, Luong R, Rosenblum MD, Steinman L, Levitsky HI, Tse V and Levy R. Depleting tumor-specific Tregs
737 at a single site eradicates disseminated tumors. *J Clin Invest*. 2013;123:2447-63.

738